Megan Shah, PharmD Candidate Cone Health Family Medicine

Slides:



Advertisements
Similar presentations
Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.
Advertisements

Treat Everyone to an LDL-C of 70mg/dl? Daniel Edmundowicz, MS, MD, FACC Associate Professor Of Medicine Director, Preventive Cardiology UPMC Cardiovascular.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Robert K Huff PharmD. Candidate May Objectives The study was designed to examine 3 main aspects Biochemical effects Safety Tolerability Evacetrapib.
News You Can Use… Pete Koval, PharmD Megan Radigan, PharmD Candidate Kira Letvak, PharmD Candidate Cone Health Family Medicine May 2015.
News You Can Use… Pete Koval, PharmD Lauren Hickman, PharmD Candidate Cone Health Family Medicine April 2015.
Michael Rollins, PharmD Candidate Cone Health Family Medicine
News You Can Use… Pete Koval, PharmD Alvin Oung, PharmD Cone Health Family Medicine March 2015.
News You Can Use… Lauren Gray, PharmD Candidate February 2015.
News You Can Use… Pete Koval, PharmD Laura Evington, PharmD candidate Cone Health Family Medicine November 2014.
News You Can Use… Pete Koval, PharmD Kim Mitchell, PharmD candidate Cone Health Family Medicine October 2014.
Zontivity™ - vorapaxar
Cone Health Family Medicine
News You Can Use… Pete Koval, PharmD Lauren Bajbus, PharmD Cone Health Family Medicine July 2014.
Iron supplements Prepared by: AbdulRahman I. Bin Muhanna.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
Prior Authorization Criteria for PDL Classes: Alzheimer’s Anti-emetics High Potency Statins Hormone Replacement Therapy Multiple Sclerosis – Tysabri Charles.
Medication Options H ealthPLACE/HOPE Program COPYRIGHT © 2002 Highmark Inc. All Rights Reserved. These materials may not be copied or otherwise reproduced.
News You Can Use… Pete Koval, PharmD Tiffany Wong, PharmD Candidate Cone Health Family Medicine June 2014.
Praluent® - alirocumab
News You Can Use… Pete Koval, PharmD Christina Adler, PharmD candidate Cone Health Family Medicine December 2014.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
News You Can Use… Stacey Karl, PharmD Pete Koval, PharmD Cone Health Family Medicine August 2015.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Tommi Cooke, PharmD Candidate 2016 Cone Health Family Medicine
News You Can Use… Josh Stewart, PharmD Candidate 2016 Pete Koval, PharmD Cone Health Family Medicine October 2015.
News You Can Use… Nick Gazda, PharmD Candidate 2016 Pete Koval, PharmD Cone Health Family Medicine December 2015.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
News You Can Use… Stacey Karl, PharmD Pete Koval, PharmD Cone Health Family Medicine January 2016.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
Persida Tahiri, PharmD Candidate 2016 Cone Health Family Medicine
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
Manufacturer: Relypsa Inc. FDA Approval Date: October 21, 2015
News You Can Use… Phillip Transou, PharmD Candidate Pete Koval, PharmD Cone Health Family Medicine June, 2016.
News You Can Use… Megan Supple, PharmD Pete Koval, PharmD Cone Health Family Medicine March 2016.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
News You Can Use… Kristen Gray, PharmD Pete Koval, PharmD Cone Health Family Medicine April 4 th, 2016.
News You Can Use… Ethan Hammer, PharmD Candidate Pete Koval, PharmD Cone Health Family Medicine August, 2016.
News You Can Use… Simone Carden, PharmD Candidate Pete Koval, PharmD Cone Health Family Medicine July, 2016.
Cone Health Family Medicine
Adam Corey, PharmD Candidate Cone Health Family Medicine
Claudia Ortiz Lopez, PharmD Candidate Cone Health Family Medicine
Rachel Kim, PharmD Candidate Cone Health Family Medicine
Claudia Ortiz Lopez, PharmD Candidate Cone Health Family Medicine
Patrick Kurunwune, PharmD Candidate Cone Health Family Medicine
Cone Health Family Medicine
Meredith Tilley, PharmD Candidate Cone Health Family Medicine
Intensive Statin Recommendations
(p < for group 1 or 2 vs. group 3)
Empagliflozin (Jardiance®)
An Endocrinology Clinic in Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Evaluating LDL-C Recommendations
62-year-old Man With Unstable Angina
% decrease in LDL-C at 24 weeks from baseline
% decrease in LDL-C at 24 weeks from baseline
Ezetimibe/simvastatin
How to Optimize Cholesterol Management in High-Risk CV Patients
ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.
A Closer Look.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Megan Shah, PharmD Candidate Cone Health Family Medicine News You Can Use… Pete Koval, PharmD Megan Shah, PharmD Candidate Cone Health Family Medicine July 2015

Drug Launched Risedronate, generic for Actonel, is now available Risedronate is used for the treatment and prevention of osteoporosis and treatment of Paget’s disease. Available as 5 mg, 30 mg, and 35 mg tablets 06/2/2015 Pharmacy Times

Trial Review IMPROVE-IT trial shows cardiac benefit of adding ezetimibe 10 mg to simvastatin 40 mg after ACS Simvastatin/ezetimibe reduced CV events by ~7% vs. simvastatin monotherapy (NNT=50) Baseline LDL of 94 mg/dl was reduced to 54 g/dl with simvastatin/ezetimibe and 70 mg/dl with simvastatin alone. 06/4/2015 N Engl J Med

Pharmacy Business CVS Health bought Target pharmacies and clinics Target pharmacies will operate under CVS name inside Target stores. Target clinics will be rebranded as MinuteClinic 06/15/2015 NY Times

New Indication Zomig (zolmitriptan) nasal spray has been FDA approved for treatment of migraines with or without aura in pediatric patients >12 years of age Previously was only indicated for age >18. Starting dose for pediatric patients is 2.5 mg daily with a max dose of 10 mg daily. 06/16/2015 Medscape

New Drug Approval Kengreal (cangrelor) gained FDA approval to prevent blood clots in patients undergoing PCI Intravenous antiplatelet drug (P2Y12 inhibitor) Administered as a 30 mcg/kg bolus injection, followed by a 4 mcg/kg/min infusion for 2 to 4 hours. 06/22/2015 FDA.gov

FDA Warning FDA issued a warning of permanent loss of skin color for Daytrana (methylphenidate) patch. Skin condition is called chemical leukoderma Time of onset ranges from 2 months to 4 years 06/24/2015 FDA.gov